VivoSeq
Gastroenterology

Cholecystitis

13

Pipeline Programs↗

2

Active Trials↗

9

Companies Involved↗

Cholecystitis is an emerging landscape with 13 programs across 9 companies. The most active players are Bayer, AstraZeneca, Teva. 7 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

15/100

Mech. Concentration

43/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 3AstraZeneca logo

AstraZeneca

1 program

Phase 3Teva logo

Teva

1 program

Phase 3P

Prism Pharmaceuticals

1 program

ApprovedShionogi logo

Shionogi

1 program

ApprovedM

Milestone Pharmaceuticals Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

15

clinical trials

Completed10 · 67%
Unknown status3 · 20%
Recruiting2 · 13%

Clinical Trials

Trial Activity

15 trials

Percutaneous or Endoscopic Gallbladder Drainage: The PEG Trial
Recruiting·OOrlando Health, Inc.·Preclinical·NCT07696546·110 enrolled
Recurrence of Acute Cholecystitis After EUS-Guided Gallbladder Drainage Versus Cholecystectomy in Elderly Patients: A Multicenter Randomized Controlled Trial
Recruiting·OOulu University Hospital·Preclinical·NCT07678541·116 enrolled
The Role of Antibiotic Treatment in Patients With Acute Mild Cholecystitis - A Prospective Randomized Controlled Trial
Completed·HHadassah Medical Organization·N/A·NCT00557453·120 enrolled
Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy
Completed·HHeidelberg University·Phase 3·NCT00447304·644 enrolled
Does it Make Sense to Give Postoperative Antibiotics to Patients With an Uncomplicated Acute Cholecystitis
Completed·UUniversity Hospital, Ghent·Phase 2·NCT00323648·50 enrolled
Fluorescent Cholangiography in Acute Cholecystitis
Completed·UUniversity Hospital of Ferrara·N/A·NCT06573021·81 enrolled
Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis
Completed·KKarolinska Institutet·Phase 3·NCT02619149·100 enrolled
Place of Antibiotics in the Postoperative Acute Lithiasic Cholecystitis
Completed·—·Phase 3·NCT01015417·414 enrolled
Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy -- Use in Acute Cholecystitis Sub-Study
Completed·OOhio State University·Phase 1·NCT02070627·6 enrolled
FDG-PET/CT in the Evaluation of Patients With Suspected Cholecystitis
Completed·—·N/A·NCT00590395·19 enrolled
Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy in Acute Cholecystitis
Completed·HHospital Italiano de Buenos Aires·Phase 4·NCT02057679·200 enrolled
Cystic Artery Preservation : an Additional Step for Safe Laparoscopic Cholecystectomy
Completed·Suez University·Preclinical·NCT07339501·200 enrolled
Indocyanine Green to Visualize Critical View of Safety During Laparoscopic Cholecystectomy for Acute Cholecystitis
Unknown status·HHamad Medical Corporation·Phase 4·NCT04624841·80 enrolled
Postoperative Pain Difference for 'IV Paracetamol' and TAP Block' in Acute Cholecystitis
Unknown status·—·Phase 3·NCT04767542·42 enrolled
Use of Indocyanine Green in Acute Cholecystitis
Unknown status·CCorporacion Parc Tauli·Phase 4·NCT05709548·440 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)